1 / 59

Phospholipids in the management of autism and degenerative neurological diseases

Phospholipids in the management of autism and degenerative neurological diseases. Victor A Marcial-Vega,MD www.marcialvegamd.com marcialvegamd@aol.com Orlando,Florida, 2013. President’s Cancer Panel Report 2010. Integrative Medicine Centers. Cleveland Clinic Johns Hopkins Hospital UCLA

sine
Download Presentation

Phospholipids in the management of autism and degenerative neurological diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phospholipids in the management of autism and degenerative neurological diseases Victor A Marcial-Vega,MD www.marcialvegamd.com marcialvegamd@aol.com Orlando,Florida, 2013

  2. President’s Cancer Panel Report 2010

  3. Integrative Medicine Centers • Cleveland Clinic • Johns Hopkins Hospital • UCLA • George Washington University • MD Anderson Cancer Center • MSK Cancer Center • Massage, Nutrition, Acupunture, Psycotherapy

  4. Integrative Medicine • Recognizes a crucial environmental role of toxins in the etiology and/or worsening of most diseases • Ex. Carbon-Petroleum based energy production, plastics, pesticides, heavy metals.

  5. Heavy Metals • Present in 100% of the population • Marker of other toxins present in organism • Higgins, 2012- Parts per trillion of mercury significant (up to 1/1,000,000,000,000) significant in production of disease

  6. 24 hour urine collectionsPuerto Rico, 2008-2012Marcial-Vega, et al, 2013 mmmmm

  7. Pre and Post EDTA Calcium

  8. PROVOCATION WITH EDTA • Conventional medicine discourages provocation because of increased toxicity • They recommend diagnosis with blood • We have found the opposite • It is both diagnostic and therapeutic under strict nutritional conditions

  9. IV Push with EDTA Calcium • 245 patients • 2010-2013 • Median Age 57 • Dose range 300-3000 mg • Median 2.4 grams

  10. IV Push with EDTA Calcium • 5 minute infusion/once a week • Lowering of total cholesterol, LDL 85% • Lowering of glucose levels 92% • Disappearance of joint pains 95% • More energy and sleeping better 100% • Marcial-Vega, 2013

  11. Retrospective Review of a Rejuvenation Program in the Management of Cancer Victor A. Marcial-Vega, MD www.marcialvegamd.com San Juan, Puerto Rico April 2013

  12. Treatment Protocol • Nutritional Supplementation • Intravenous Vitamin C (+ or - EDTA) • Ozone/Hyperthermia showers

  13. Intravenous Therapy • Vitamin C 20 grams • Vitamins B1, B6(100 mg), B12 (1000ug) • Sterile water(250 cc) • EDTA 2-6 cc(3g/21cc)

  14. Intravenous Therapy • Three times a week • 20 gram weekly increases until 70 grams or tolerance is reached • Dose range 50-70 grams

  15. Ozone/Hyperthermia Showers • 5 days a week • 1/2 hour treatments • 98-103 degrees Fahrenheit

  16. Results • Age Range 8-80 years Median 56 years • Median Follow-up 18 months • Analysis on 40 patients

  17. Initial Response • More than 50% reduction of tumor • Within 3 weeks • (A) 25/33= 76% • (B) 3/5 = 60% • (C) 1/2 = 50% • Overall = 72%

  18. 18 months results • No tumor after multiple recurrences 2/33 • Complete Response 6/33 • Partial 6/33 • Total 14/33=42%

  19. Symptoms • Improvement in 80% first 2 weeks • Sustained at 5 months in 50%

  20. Memory and Awareness • Most patients report an improvement in cognitive, memory and focusing • Brain characteristics • This is an indicator of correlation between toxins and brain function

  21. Phospholipids • Plaquex • In the management of cardiovascular diseases and detoxification • Our clinic in Miami started managing and detoxing patients with IV phosphatidylcholine

  22. Neurological Diseases Adults • More than 85% of Alzheimer’s Disease patients will have an MRI or CT scan showing white matter changes consistent with small vessel ischemic disease. • A disease of brain toxicity • Fourth leading cause of death in Puerto Rico. 6th in the USA

  23. Alzheimer’s Disease • Gochi, Chlorella, Vitamin C and Lactobacillus • Alkalinizing Program • Intravenous phosphatidylcholine • 250-1500 mg IV Push or IV bag in D5W • B12, Glutathione • Weekly

  24. Alzheimer’s • 25 patients • Marked improvement in 72% of the patients • 2 had no response (8%) • 20% Moderate response • EDTA and Phosphatidylcholine

  25. Dementia • 10 patients • Marked improvement in most of their cognitive capacities • Improvement in socialization and orientation to place • Last aspect to improve-Short term memory

  26. Parkinson’s Disease • 5 patients • Steady improvement in the first 2 months in 3/5 • 1 patient –No change • 1 patient-Dramatic improvement and reversal of all symptoms with PTC and pulsed electromagnetic frequency • All patients now get PEMF

  27. Chemotherapy Induced Neuropathy • Cisplatin, Carboplatin associated • Very painful • Feet and hands • Does not respond well to analgesics

  28. Neuropathy • Management with phosphatidylcholine • 10 patients • Weekly • Improvement in all patients in the first two treatments • Complete Resolution of pain in 8 pts. • The earlier the better

  29. ALS • 8 patients • One-EDTA, IVC, H2O2-no response. Died in less than a year • 2 more with PTC-No response • 1 Pt. with 3x/day tx 15 txs. Week • First week regained vocal cord and swallowing movement

  30. ALS • Stopped treatment after 3 months and deteriorated • One patient was stable for one year speaking and walking. Died from a fall • One patient improved and spasticity markedly improved with PTC and PEMF

  31. ALS • Latest 2 patients • #1 in less than 2 weeks could understand previously unintelligible speech. Swallowing better. • Improved pulmonary function studies • #2 Could move extremities better in 2 weeks • Both had daily treatment

  32. Side Effects • Temporary (minutes) dizziness-2 • Extravasation and burning that would last days, weeks and sclerose veins temporarily 4% • Months of sclerosing 3 patients

  33. AUTISM • 1:37 in Puerto Rico • 1:50-75 in the USA • No more figures presented in CDC website since 2008 • Rapidly rising epidemic • Maybe related to aluminum and mercury in vaccines

  34. AUTISM • 75 patients • 7 Did not complete treatment • Of the 68 remaining patients • Analysis • 75% trigered at 18 months of age related to vaccine booster doses

  35. AUTISM • Eliminate sugar, complex carbohydrates • Start nutritional alkalinization • Intravenous phosphatidylcholine • 250-1000 mg a week • Glutathione IV 400 mg a week • Methylcobalamin 1000 ug • Folic acid 4 mg

  36. AUTISM • After 10-20 Weekly treatments • IV Phenylbutyrate 100-400 mg in 100 cc/d5w • Continue if there was a steady improvement • Side effects- Rash in 2 patients. Glutathione eliminated in them and it resolved. They were both allergic to eggs

More Related